Specifying the behavior of concurrent systems

A framework for rigorously specifying the behavior of concurrent systems is proposed. It is based on the view of a concurrent system as a collection of interacting processes but no assumptions are made about the mechanisms for process synchronization and communication. A formal language is described that permits the expression of a broad range of logical and timing dependencies

Cloning and characterization of MADS-box gene in oil palm

Oil palm has emerged as one of the most important source of oils and fats. The mechanism of floral organs development in this plant is still at its infancy. We describe here the cloning and characterization of a MADS-box gene in oil palm (Elaeis guineensis Jacq.) named EMADS1. It belongs to the AGAMOUS-like2 family of MADS-box gene which plays critical role in flower development as defined by the ABCDE model. EMADS1 was ubiquitously expressed in the immature male and female flower buds and its expression pattern was similar to EgAGL2 and EgMADS8 of oil palm. The EMADS1 transcript also accumulated in embryos of developing seeds. These results suggested that EMADS1 is likely to function at the initial stages of flowering in determination of the inflorescence and the identity of the flower whorls and also embryo development in seeds

Wild boar population at the Vistula Spit – management of the species in forested and urban areas

Bobek, B., Frąckowiak, W., Furtek, J., Merta, D., Orłowska, L

Reproductive parameters, birth date-effect and body condition of wild boars (Sus scrofa) inhabiting forest and forest-farmland environments in Poland

Merta, D., Albrycht, M., Frąckowiak, W., Furtek, J., Mamok, T

Further Analyses of the Safety of Verubecestat in the Phase 3 EPOCH Trial of Mild-To-Moderate Alzheimer’s Disease

Background: Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the development of BACE1 inhibitors, we report detailed safety findings from EPOCH. Methods: EPOCH was a randomized, double-blind, placebo-controlled 78-week trial evaluating verubecestat 12 mg and 40 mg in participants with mild-to-moderate AD diagnosed clinically. The trial was terminated due to futility close to its scheduled completion. Of 1957 participants who were randomized and took treatment, 652 were assigned to verubecestat 12 mg, 652 to verubecestat 40 mg, and 653 to placebo. Adverse events and relevant laboratory, vital sign, and ECG findings were assessed. Results: Verubecestat 12 mg and 40 mg were associated with an increase in the percentage of participants reporting adverse events versus placebo (89 and 92% vs. 82%), although relatively few participants discontinued treatment due to adverse events (8 and 9% vs. 6%). Adverse events that were increased versus placebo included falls and injuries, suicidal ideation, weight loss, sleep disturbance, rash, and hair color change. Most were mild to moderate in severity. Treatment differences in suicidal ideation emerged within the first 3 months but did not appear to increase after 6 months. In contrast, treatment differences in falls and injuries continued to increase over time. Conclusions: Verubecestat was associated with increased risk for several types of adverse events. Falls and injuries were notable for progressive increases over time. While the mechanisms underlying the increased adverse events are unclear, they may be due to BACE inhibition and should be considered in future clinical development programs of BACE1 inhibitors

National Atomic Energy Agency - past and present

27 lutego br. minęła 36 rocznica utworzenia Państwowej Agencji Atomistyki (PAA) – urzędu odpowiedzialnego w Polsce za nadzór i kontrolę w sprawach wykorzystania energii atomowej, w tym za nadzór nad bezpieczeństwem jądrowym i ochroną radiologiczną. Początki planów dotyczących przemysłowego wykorzystania energii jądrowej w Polsce można datować na rok 1956. Wtedy utworzono urząd Pełnomocnika Rządu ds. Wykorzystania Energii Jądrowej z organem doradczym pod nazwą Państwowa Rada ds. Wykorzystania Energii Atomowej. Urząd Pełnomocnika został w 1973 r. zastąpiony Urzędem Energii Atomowej. Od roku 1976 sprawami atomistyki zajmowało się Ministerstwo Energetyki i Energii Atomowej. Lata 1981-1982 to okres funkcjonowania Pełnomocnika Rządu ds. Atomistyki. Ostatecznie w 1982 r. powołano Państwową Agencję Atomistyki. W artykule przedstawiono krótki rys historyczny i przedstawiono PAA jako nowoczesny dozór jądrowy, przygotowany do pełnienia funkcji dozorowych dla rozwijanej w Polsce energetyki jądrowej.February 27th this year marks 36th the anniversary of the establishment of the National Atomic Energy Agency (PAA) - the office responsible for supervision and control of matters of the use of nuclear energy in Poland, including the supervision of nuclear safety and radiological protection. The beginnings of plans for the industrial use of nuclear energy in Poland can be dated back to 1956. At that time, the office of the Government Plenipotentiary for the Use of Nuclear Energy was created with an advisory body under the name State Council for the Use of Atomic Energy. The Office of the Plenipotentiary was replaced in 1973 by the Atomic Energy Office. Since 1976, the Ministry of Energy and Atomic Energy has been involved in atomic matters. 1981-1982 was the period of functioning of the Government Plenipotentiary for Atomic Energy. Finally, in 1982, the National Atomic Energy Agency was established. The article presents a historical sketch and the PAA as a modern nuclear regulator, well prepared to perform regulatory functions for the nuclear power developed in Poland

The logic of systems.

Thesis. 1976. Ph.D.--Massachusetts Institute of Technology. Dept. of Electrical Engineering and Computer Science.Microfiche copy available in Archives and Engineering.Bibliography: p.173-174.Ph.D